Pooled 5-FU Population PK Model Supports Lean Mass and Model-Informed Dosing

This individual patient data meta-analysis builds a generalizable population pharmacokinetic model for intravenous 5-fluorouracil and offers simulated evidence that model-informed precision dosing outperforms conventional therapeutic drug monitoring for reaching target exposure.

5-fluorouracilfluoropyrimidinescolorectal cancerpopulation pharmacokineticsmodel-informed precision dosingtherapeutic drug monitoringlean body massNONMEMIPD meta-analysisoncology Pharmacokinetics / TDM

Background Information

Leverage lean body mass for precise 5-FU dosing!

Understanding the pharmacokinetics of 5-fluorouracil is crucial for optimizing dose and therapeutic efficacy, especially in colorectal cancer treatment. A model-based approach using lean body mass and model-informed precision dosing improves target attainment significantly better than traditional TDM methods. The study suggests a shift towards lean body mass-based dosing and model-informed strategies, which could reduce variability seen with body-surface area dosing. Utilizing lean body mass and model-informed precision dosing can enhance therapeutic outcomes in 5-fluorouracil therapy.

📊 Deep Analysis Available

Subscribers get the full breakdown: study design, outcomes, pharmacist implications, clinical pearls, GRADE evidence grade, and a downloadable PDF report.

Subscribe for Full Access →

Authors: Briki M, Thoueille P, Joerger M, Chatelut E, Sterle M, Schmitt A, Wagner AD, Buclin T, Carrara S, Guidi M

Citation: Briki M, Thoueille P, Joerger M, et al. Model-based meta-analysis of individual patient data for the characterization of intravenous 5-fluorouracil population pharmacokinetics. Cancer chemotherapy and pharmacology. 2026;96(1). doi:10.1007/s00280-026-04885-x

Article Links: PubMed · Journal / DOI

🎓

Reviewed by a licensed pharmacist

Every analysis is reviewed and approved by a licensed pharmacist before publication, ensuring clinical accuracy and relevance.

Accurate and up-to-date information is our highest priority.

If you spot an error, please suggest a correction. If there is a topic you want covered, tell us and we will look at it.

Suggest a correction Request a topic

Thanks for the feedback!

🔒

Deep Analysis: Subscribers Only

Subscribers receive access to a complete clinical analysis, available online and as a downloadable PDF.

Executive Summary

Study Design

Patient Population

Primary Outcomes

Secondary Outcomes & Safety Profile

Pharmacist Implications

Clinical Pearls

Limitations

Controversies & Evidence Gaps

Cost & Logistics

Want the full analysis?

Subscribe to PharmD Signal for unrestricted access to every deep analysis, plus PDF reports, GRADE evidence grades, and pharmacist implications for every article we publish.

Become a Subscriber →